Postural Orthostatic Tachycardia Syndrome (POTS)
Authors:
- 6 October 2026
- journal article
- Published by American Medical Association (AMA) in JAMA
- Vol. 336 (13) , 1149
Abstract
Importance: Postural orthostatic tachycardia syndrome (POTS) is a chronic autonomic disorder characterized by excessive orthostatic tachycardia and multisystem symptoms that affects an estimated 0.1% to 1% of the US population. POTS can substantially impair daily functioning and quality of life. Observations: Consensus criteria define POTS by chronic symptoms of orthostatic intolerance accompanied by a sustained heart rate increase of at least 30 beats/min (≥40 beats/min in adolescents aged 12-19 years) within 10 minutes of standing or head-up tilt from a supine position in the absence of orthostatic hypotension, defined as a decrease in either systolic blood pressure of at least 20 mm Hg or diastolic blood pressure of at least 10 mm Hg with positional change. POTS symptoms may include palpitations, lightheadedness, nausea, vomiting, gastroparesis, anorexia, generalized weakness, and muscle pain, despite absence of structural pathology within cardiovascular, gastrointestinal, and neurological organs. POTS predominantly affects females (approximately 90% of cases), with peak incidence from ages 13 to 29 years. However, the true prevalence remains uncertain partly due to underrecognition and lack of a specific diagnostic code for POTS until 2022. Common symptoms include lightheadedness, palpitations, fatigue, cognitive dysfunction (“brain fog”), exercise intolerance, nausea, bloating, constipation, diarrhea, and sleep disturbance. In a survey of 4835 patients, approximately 70% reported substantial functional impairment and loss of school or work participation, and median diagnostic delay was 24 months. In 30% to 40% of cases, symptoms began within 3 months after infections, such as SARS-CoV-2, Epstein-Barr virus, and influenza. Initial evaluation should exclude other conditions that cause sinus tachycardia, including thyroid disease, adrenal insufficiency, pheochromocytoma, cardiomyopathy, valvular heart disease, congenital heart disease, chronic lung disease, medication effects (eg, stimulants, norepinephrine reuptake inhibitors, and diuretics), anemia, and dehydration. First-line treatment includes nonpharmacological strategies to improve cardiac preload, including increased fluid and sodium intake, lower-body compression garments; avoidance of heat exposure, dehydration, and prolonged standing; and structured supervised aerobic training. Pharmacological therapies should be individualized and may include β-blockers, ivabradine, midodrine, fludrocortisone, and pyridostigmine, although evidence supporting many therapeutic interventions is limited by small studies and lack of large, randomized trials. Conclusions and Relevance: POTS is a chronic autonomic disorder associated with functional impairment and reduced quality of life that is diagnosed based on characteristic orthostatic symptoms in the absence of orthostatic hypotension after excluding alternative causes of sinus tachycardia. Treatment involves nonpharmacological measures (such as increased fluid and sodium intake), lower-body compression garments, structured exercise training, and individualized pharmacological therapy.Keywords
This publication has 103 references indexed in Scilit:
- Chronic autonomic symptom burden in long-COVID: a follow-up cohort studyClinical Autonomic Research, 2025
- Tilt Table TestingJAMA, 2024
- Prevalence of orthostatic intolerance in long covid clinic patients and healthy volunteers: A multicenter studyJournal of Medical Virology, 2024
- Semi-supervised exercise training program more effective for individuals with postural orthostatic tachycardia syndrome in randomized controlled trialClinical Autonomic Research, 2023
- Autonomic dysfunction in post-COVID patients with and witfhout neurological symptoms: a prospective multidomain observational studyJournal of Neurology, 2021
- Body Mass Index (BMI) is Associated with the Therapeutic Response to Oral Rehydration Solution in Children with Postural Tachycardia SyndromePediatric Cardiology, 2016
- Small‐fiber neuropathy with cardiac denervation in postural tachycardia syndromeMuscle & Nerve, 2014
- Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human BrainJAMA, 2009
- Mechanisms of blood pressure alterations in response to the Valsalva maneuver in postural tachycardia syndrome.Clinical Autonomic Research, 2000
- Hemodynamic and symptomatic effects of acute interventions on tilt in patients with postural tachycardia syndromeClinical Autonomic Research, 2000